Spots Global Cancer Trial Database for Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
Official Title: A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin'd Lymphoma (NHL)
Study ID: NCT00515892
Study Description
Brief Summary: RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have Non-Hodgkin's lymphoma and do not respond to treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tower Hematology Oncology Medical Group, Beverly Hills, California, United States
Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Klinika Hamtologii Uniwersytetu Medycznego (Medical University of Lodz), Lodz, , Poland
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
